Clinical Trials | December 27, 2025
InnoCare Pharma gets green light for Phase II trial of oral lupus drug
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
This production milestone positions Symbiosis at the forefront of meeting rising global demand for life-saving medicines
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
The therapy targets the LRRC15 protein and is designed for enhanced tumor penetration and differentiated anti-tumor activity in solid tumors with the highest unmet needs.
The study found that nerandomilast effectively slowed lung function decline in patients, with discontinuation rates similar to placebo
The Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of ENV-6946 in healthy volunteers
Adverse events were consistent with valbenazine’s established safety profile
Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
Subscribe To Our Newsletter & Stay Updated
